Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 07, 2016 08:00 ET | Source: Genticel S.A.

Genticel to Evaluate Roche Molecular Systems’ cobas® HPV Test in Preparation for Phase 3 Program of GTL001

PARIS and TOULOUSE, France, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
January 05, 2016 16:01 ET | Source: Genticel S.A.

Genticel Appoints Remi Palmantier, PhD, as Chief Scientific Officer to Accelerate Its Development

PARIS and TOULOUSE, France, Jan. 05, 2016 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
October 29, 2015 16:01 ET | Source: Genticel S.A.

Genticel Announces First Patient Treated in U.S. Phase 1 Clinical Trial of GTL001, Company's Therapeutic Vaccine Candidate against HPV 16/18 Infections

PARIS and TOULOUSE, France, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
September 21, 2015 16:01 ET | Source: Genticel S.A.

Genticel Presents First Half 2015 Financial Results, Operational Progress & Outlook

PARIS and TOULOUSE, France, Sept. 21, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of...
September 08, 2015 07:30 ET | Source: Genticel S.A.

US Patent Granted for Use of Genticel's Antigen Delivery Vectors in Combination Therapy to Treat Cancer

PARIS and TOULOUSE, France, Sept. 8, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a clinical-stage biotechnology company and developer of innovative...
July 07, 2015 16:05 ET | Source: Genticel S.A.

Independent Data Safety Monitoring Board Recommends Continuation per Protocol of Genticel's Phase 2 Clinical Trial of GTL001 (ProCervix), Company's First-in-class HPV Therapeutic Vaccine Candidate

Half of the 236 vaccinated patients have reached the 12-month follow-up milestone Patient and physician engagement remains very strong with 98% retention rate* PARIS and TOULOUSE, France,...
June 16, 2015 08:00 ET | Source: Genticel S.A.

Genticel Receives FDA Clearance of IND Application for US Phase 1 Clinical Trial of GTL001 (ProCervix), Company's First-in-Class HPV Therapeutic Vaccine Candidate

PARIS and TOULOUSE, France, June 16, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a French biotechnology company and developer of innovative...
June 01, 2015 08:00 ET | Source: Genticel S.A.

Genticel Announces Positive Preclinical Proof of Concept Results of GTL002, Its New Multivalent HPV Therapeutic Vaccine Candidate Based on Company's Versatile Vaxiclase Platform

PARIS and TOULOUSE, France, June 1, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a French biotechnology company and developer of innovative...
April 20, 2015 13:00 ET | Source: Genticel S.A.

Genticel to Present Further Promising Pharmacology In-Vivo Results of Its Phase 2 Immunotherapeutic Vaccine Candidate, GTL001 (ProCervix), at AACR Annual Meeting 2015

PARIS and TOULOUSE, France, April 20, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a French biotechnology company and developer of innovative...
April 09, 2015 16:58 ET | Source: Genticel S.A.

Genticel Strengthens Management Team and Appoints Valerie Leroy as Senior Director, Corporate Communications and Investor Relations

PARIS and TOULOUSE, France, April 9, 2015 (GLOBE NEWSWIRE) -- Genticel (Euronext Paris & Brussels: FR00011790542 – GTCL), a French biotechnology company and developer of innovative...

keyboard_arrow_left Previous Page